St John's DermAcademy Podcasts
by Dr Sarah Drummond

Episode 14: Immunobullous disorders - Part 1: Bullous pemphigoid

Dr Thomas Tull
BSc (hons), MBBS, PhD, MRCP (UK)

Consultant Dermatologist, St John's Institute of Dermatology
Guy's and St Thomas' NHS Foundation Trust

In this episode we discuss…

- The clinical features and risk factors for developing bullous pemphigoid
- How to differentiate bullous pemphigoid from other subepidermal blistering disorders
- Management of bullous pemphigoid including:
    - Preferred first and second line agents
    - How and when to reduce treatment
    - What to do in severe and refractory cases

Resources and further reading:

- European guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology, 2022 (updated) (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220)
- British Association of Dermatologists' guidelines for the management of bullous pemphigoid, 2012 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072)

Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series.